Anthera acquires troubled Sollpura from Lilly
This article was originally published in Scrip
Executive Summary
Anthera Pharmaceuticals acquired Sollpura (liprotamase), a non-porcine pancreatic enzyme replacement therapy (PERT) with a long and troubled history in exocrine pancreatic insufficiency (EPI), from Eli Lilly for an undisclosed price.